Going by the historical performance, we believe that the stock price of Mylan (NYSE: MYL), a pharmaceutical company best known for its generic drugs, could offer an upside of over 45% from the current ...
MYL-1701P displayed similar efficacy, safety, and immunogenicity when compared with reference aflibercept to treat diabetic macular edema. Aflibercept is an intravitreal drug approved by the FDA for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results